Literature DB >> 28130399

Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.

Uri Rozovski1,2,3, David M Harris1, Ping Li1, Zhiming Liu1, Preetesh Jain1, Ivo Veletic1, Alessandra Ferrajoli1, Jan Burger1, Susan O'Brien1, Prithviraj Bose1, Philip Thompson1, Nitin Jain1, William Wierda1, Michael J Keating1, Zeev Estrov4.   

Abstract

In chronic lymphocytic leukemia (CLL), STAT3 is constitutively phosphorylated on serine 727 and plays a role in the pathobiology of CLL. However, what induces constitutive phosphorylation of STAT3 is currently unknown. Mass spectrometry was used to identify casein kinase 2 (CK2), a serine/threonine kinase that coimmunoprecipitated with serine phosphorylated STAT3 (pSTAT3). Furthermore, activated CK2 incubated with recombinant STAT3 induced phosphorylation of STAT3 on serine 727. Although STAT3 and CK2 are present in normal B- and T cells, STAT3 is not constitutively phosphorylated in these cells. Further study found that CD5 and BLNK coexpressed in CLL, but not in normal B- or T cells, are required for STAT3 phosphorylation. To elucidate the relationship of CD5 and BLNK to CK2 and STAT3, STAT3 was immunoprecipitated from CLL cells, and CK2, CD5, and BLNK were detected in the immunoprecipitate. Conversely, STAT3, CD5, and BLNK were in the immunoprecipitate of CLL cells immunoprecipitated with CK2 antibodies. Furthermore, siRNA knockdown of CD5 or BLNK, or treatment with CD5-neutralizing antibodies significantly reduced the levels of serine pSTAT3 in CLL cells. Finally, confocal microscopy determined that CD5 is cell membrane bound, and fractionation studies revealed that the CK2/CD5/BLNK/STAT3 complex remains in the cytoplasm, whereas serine pSTAT3 is shuttled to the nucleus.Implications: These data show that the cellular proteins CK2, CD5, and BLNK are required for constitutive phosphorylation of STAT3 in CLL. Whether this protein complex phosphorylates other proteins or inhibiting its activity would have clinical benefit in patients has yet to be determined. Mol Cancer Res; 15(5); 610-8. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28130399      PMCID: PMC5415425          DOI: 10.1158/1541-7786.MCR-16-0291

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

Review 1.  Functional roles of STAT family proteins: lessons from knockout mice.

Authors:  S Akira
Journal:  Stem Cells       Date:  1999       Impact factor: 6.277

2.  Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

Authors:  L R Martins; P Lúcio; A Melão; I Antunes; B A Cardoso; R Stansfield; M T S Bertilaccio; P Ghia; D Drygin; M G Silva; J T Barata
Journal:  Leukemia       Date:  2013-08-08       Impact factor: 11.528

3.  Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

Authors:  Medhat Shehata; Susanne Schnabl; Dita Demirtas; Martin Hilgarth; Rainer Hubmann; Elena Ponath; Sigrun Badrnya; Claudia Lehner; Andrea Hoelbl; Markus Duechler; Alexander Gaiger; Christoph Zielinski; Josef D Schwarzmeier; Ulrich Jaeger
Journal:  Blood       Date:  2010-06-24       Impact factor: 22.113

4.  Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.

Authors:  Uri Rozovski; Srdana Grgurevic; Carlos Bueso-Ramos; David M Harris; Ping Li; Zhiming Liu; Ji Yuan Wu; Preetesh Jain; William Wierda; Jan Burger; Susan O'Brien; Nitin Jain; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2015-03-02       Impact factor: 5.852

5.  Augmentation of signal transducer and activation of transcription (STAT)6 and STAT3 expression in stimulated B and T cells.

Authors:  Y Arinobu; R Sugimoto; M Akaiwa; K Arima; T Otsuka; N Hamasaki; K Izuhara
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

6.  Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.

Authors:  Ping Li; David Harris; Zhiming Liu; Jie Liu; Michael Keating; Zeev Estrov
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

7.  Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells.

Authors:  Suparna Mishra; Anja Reichert; Jess Cunnick; Dinithi Senadheera; Bianca Hemmeryckx; Nora Heisterkamp; John Groffen
Journal:  Oncogene       Date:  2003-11-13       Impact factor: 9.867

8.  Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.

Authors:  Marco Pizzi; Francesco Piazza; Claudio Agostinelli; Fabio Fuligni; Pietro Benvenuti; Elisa Mandato; Alessandro Casellato; Massimo Rugge; Gianpietro Semenzato; Stefano A Pileri
Journal:  Oncotarget       Date:  2015-03-30

9.  Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.

Authors:  Ping Li; Srdana Grgurevic; Zhiming Liu; David Harris; Uri Rozovski; George A Calin; Michael J Keating; Zeev Estrov
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

10.  Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Authors:  Sabrina Manni; Alessandra Brancalion; Elisa Mandato; Laura Quotti Tubi; Anna Colpo; Marco Pizzi; Rocco Cappellesso; Fortunato Zaffino; Speranza Antonia Di Maggio; Anna Cabrelle; Filippo Marino; Renato Zambello; Livio Trentin; Fausto Adami; Carmela Gurrieri; Gianpietro Semenzato; Francesco Piazza
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

View more
  9 in total

1.  STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Orit Uziel; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

Review 2.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 3.  Therapeutic targeting of CK2 in acute and chronic leukemias.

Authors:  F Buontempo; J A McCubrey; E Orsini; M Ruzzene; A Cappellini; A Lonetti; C Evangelisti; F Chiarini; C Evangelisti; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2017-09-27       Impact factor: 11.528

4.  Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival.

Authors:  Jordi Vilardell; Estefania Alcaraz; Eduard Sarró; Enric Trilla; Thaïs Cuadros; Inés de Torres; Maria Plana; Santiago Ramón Y Cajal; Lorenzo A Pinna; Maria Ruzzene; Juan Morote; Anna Meseguer; Emilio Itarte
Journal:  Oncotarget       Date:  2017-12-19

Review 5.  The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.

Authors:  Loukik Arora; Alan Prem Kumar; Frank Arfuso; Wee Joo Chng; Gautam Sethi
Journal:  Cancers (Basel)       Date:  2018-09-13       Impact factor: 6.639

6.  STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Taghi Manshouri; Ivo Veletic; Alessandra Ferrajoli; Prithviraj Bose; Phillip Thompson; Nitin Jain; Srdan Verstovsek; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Oncotarget       Date:  2021-03-02

Review 7.  Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.

Authors:  Zaira Spinello; Anna Fregnani; Laura Quotti Tubi; Livio Trentin; Francesco Piazza; Sabrina Manni
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

Review 8.  CSNK2 in cancer: pathophysiology and translational applications.

Authors:  Scott W Strum; Laszlo Gyenis; David W Litchfield
Journal:  Br J Cancer       Date:  2021-11-12       Impact factor: 9.075

9.  Identification of novel regulators of STAT3 activity.

Authors:  Elina Parri; Heikki Kuusanmäki; Arjan J van Adrichem; Meri Kaustio; Krister Wennerberg
Journal:  PLoS One       Date:  2020-03-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.